Eli Lilly Is Being Paid to Give Away Price, The Market Is Fixated on the Wrong Risk
Thirteen per cent less price. Sixty per cent more volume. Gross margin up a point and a half anyway. That single line from Eli Lilly's June-quarter results, reported on 5 August, is the whole investment case and the whole argument against it, depending on which number you stare at .
Lilly is not a diversified pharmaceutical conglomerate in any operating sense — it reports as one segment, human pharmaceutical products, sold in roughly 90 countries . What it is, in practice, is a cardiometabolic franchise with four smaller businesses attached. Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, generated $14.9bn of the quarter's $22.97bn ($9.94bn and $4.93bn respectively), and the pair accounted for 56 per cent of 2025 revenue . Around that sit oncology (Verzenio, Jaypirca, Retevmo, the newly launched oral SERD Inluriyo), immunology (Taltz, Omvoh, the atopic-dermatitis biologic Ebglyss), neuroscience (Emgality and the Alzheimer's antibody Kisunla), and a legacy insulin and Jardiance book that still throws off cash while it decays. Strip out the eight products Lilly designates "Key Products" — $15.7bn in the quarter — and roughly $7.3bn of quarterly revenue still comes from everything else .
The stock sits about 11% below the record set on August 19th and roughly 60% above the low struck a year earlier . That give-back is the setup. Nothing broke: what happened in the second half of August was a cardiovascular approval that cleared the bar it was designed to clear and no higher, a fresh round of Washington price-setting that reminded everyone the policy regime is permanent, and another multi-billion-dollar acquisition. The market read all three as reasons to take profits. Two of them are, in my reading, misread — and the third is the risk almost nobody is pricing.
The trade: giving up price on purpose, and widening margins while doing it
The mechanic that governs this business is not demand. It is the spread between how fast realised price falls and how fast unit cost falls. In the June quarter worldwide revenue rose 48 per cent on a 60 per cent volume gain against a 13 per cent decline in realised prices — and reported gross margin still expanded 1.5 points to 85.8 per cent of revenue, which management attributed to improved cost of production and favorable mix . On the non-GAAP basis the company guides to, gross margin was 86.3 per cent, up 1.3 points .
That is the opposite of what a franchise under pricing attack looks like. It is what a manufacturer looks like when the capacity it spent three years building starts absorbing fixed cost. The scale of that build is easy to underestimate: capital investments in PP&E ran $3.45bn in 2023, $5.06bn in 2024 and $7.84bn in 2025 , roughly $16.3bn cumulatively, over a period in which annual revenue went from $34.1bn to $65.2bn . Roughly $31bn of incremental annual revenue at an 84 per cent-plus gross margin, against $16bn of cumulative plant spend, is a return on physical capital far above any plausible cost of capital — and the spend is still accelerating, with $5.26bn of PP&E spend in the first half of 2026 alone . On a heavy re-investor, the question is never how much is being spent; it is the spread earned on it. Here the spread is not close.
The price side is genuinely being legislated, and Lilly volunteered for it. Its most-favoured-nation arrangement with the administration produced the Medicare GLP-1 Bridge, which from 1 July gives eligible Part D beneficiaries obesity coverage at a $50 monthly copay against a $245 net price to CMS, and has since been extended through the end of 2027 . Management's framing on the August call — that roughly 20 million Americans became eligible and coverage for its obesity medicines widened by about 35 per cent — matters less than the arithmetic underneath it: the White House reported more than 500,000 seniors using the programme in its first two months . A price cut that buys that much reimbursed volume is not a concession. It is a distribution deal.
Management is explicit that more price is coming and that volume is expected to more than offset it — the CFO said as much when pressed on Zepbound net pricing, flagging that regaining CVS Caremark formulary access from the fourth quarter will itself pull realised price lower . The Caremark point is worth pausing on, because the exclusion that began in July 2025 was disclosed in the annual report as an access headwind ; its reversal is a volume tailwind the guidance already carries.
The growth is no longer where the bears are looking
The lazy version of this story is "US obesity, saturating." The quarter says otherwise. US revenue grew 33 per cent on 37 per cent volume against a 3 per cent price decline — flattered by rebate true-ups, without which US price would have fallen about 9 per cent — while revenue outside the US grew 80 per cent on 113 per cent volume against a 36 per cent price decline driven by Mounjaro's addition to China's national reimbursement list . Ex-US Mounjaro reached $5.2bn, up 172 per cent, and now runs ahead of the $4.8bn US book . Lilly holds roughly 60.9 per cent of the US incretin analogue market and about 54.9 per cent internationally on IQVIA data .
The second leg is smaller but real: key products in immunology, oncology and neuroscience grew 121 per cent year on year, with Ebglyss up 131 per cent, Kisunla up from a $49m base to $167m, and Jaypirca up 56 per cent . None of these will move a $1tn market capitalisation on its own. Collectively they are the beginning of an answer to concentration — the same annual report that flags 56 per cent tirzepatide dependence also notes that six products supplied 82 per cent of 2025 revenue, and that Trulicity loses significant patent and data protection within the next few years .
The 28 August cardiovascular approval belongs in this section rather than in the catalyst column, and I want to be precise about it. SURPASS-CVOT enrolled 13,299 patients and tested tirzepatide against Trulicity — an active comparator with established cardiovascular benefit, not placebo. Mounjaro met non-inferiority with a hazard ratio of 0.92 (95.3 per cent CI 0.83–1.01); superiority was not established . This is a formulary and guideline unlock, not an efficacy differentiator, and the stock's flat reaction was correct on the day. Its value is that it removes the last clinical objection a payer could raise to tirzepatide as first-line therapy in high-risk type 2 diabetes — the largest reimbursed pool Lilly serves.
Cash conversion already inflected, and almost nobody has updated
The most-cited bear argument on Lilly for three years has been that the earnings are not cash-backed: free cash flow was under $1bn in 2023, on $4.24bn of operating cash flow against $3.45bn of capital expenditure, and stayed thin through 2024 as inventory and receivables absorbed the growth . That objection is now stale. First-half 2026 operating cash flow was $16.02bn against $5.26bn of capital expenditure — roughly $10.8bn of free cash flow, versus about $1.5bn in the comparable 2025 period on $4.75bn of operating cash flow and $3.21bn of capex . Measured against first-half net income of $14.49bn, conversion moved from about 18 per cent to about 74 per cent . Full-year 2025 already showed the turn beginning, with $16.81bn of operating cash flow and $7.84bn of capex .
The working-capital absorption was the capacity build. The build is now producing. Anyone still quoting the multi-year gap between cash flow and earnings is quoting a fact the tape has overtaken.
The $23bn the market is crediting at the wrong multiple
Here is where I part company with the consensus enthusiasm, and it is not the price line.
Lilly paid $13.3bn for business development in the first half of 2026 alone, across Centessa, Kelonia, Orna, Ventyx and Ajax . It then spent roughly $2.0bn in July on three infectious-disease acquisitions, agreed to buy AtaiBeckley for approximately $2.8bn at closing , and on 31 August agreed to acquire Merida Biosciences for up to $2.88bn in cash . Total debt went from $42.5bn at the end of 2025 to $54.9bn at 30 June, including a $9bn bond issue in May .
The assets are almost uniformly early. Ajax's lead JAK2 inhibitor and Orna's in-vivo CAR-T programme were both Phase 1 at acquisition, and their costs — $909m and $1,233m respectively — were expensed straight to the income statement as acquired in-process R&D . The Kelonia and Centessa business combinations added $4.7bn and $6.1bn of indefinite-lived IPR&D intangibles to the balance sheet, with a further $3.75bn and $1.54bn of contingent consideration behind them .
I understand the logic. A company deriving more than half its revenue from one molecule, generating this much cash, would be negligent not to diversify. But diversification bought at $2bn–$6bn per Phase 1 programme has a completely different return profile from the manufacturing build, and the market is quietly valuing both at the incretin franchise's multiple. That is the slice of the story I do not think is priced — not as a fraud flag or a thesis-breaker, but as a slow drag on per-share compounding that will only be legible in hindsight. It is the reason I think 24x is the right number to pay here and 28x would not be.
Where this could actually go wrong: the accrual, the oral race, and the ex-US reset
Three risks deserve serious weight, and only one of them is the one the headlines cover.
The first is an earnings-quality question hiding in plain sight. Lilly's revenue is reported net of an enormous rebate estimate: sales rebates and discounts on the balance sheet stood at $21.12bn at 30 June, up from $17.38bn at the end of 2025 . The auditor designated exactly this — Medicaid, Managed Care and Medicare rebate accruals — as the critical audit matter in the 2025 audit, noting the subjectivity of the assumptions and that historical rebate data may not be predictive . Both of the last two quarters have carried favourable pre-period adjustments to those estimates; management flagged them, and without them US price would have fallen about 9 per cent rather than 3 per cent in the second quarter . That is not an allegation of anything. It is a statement that a meaningful slice of recent reported price performance rests on a management estimate that the auditor considers the hardest judgement in the accounts, and that the estimate is running larger every quarter as the channel mix shifts toward government and cash-pay.
The second is the oral race, which Lilly is currently losing on cadence. Foundayo, its oral GLP-1, generated $98m in its first partial quarter . Novo Nordisk's oral Wegovy did several times that in the same period. Foundayo is under regulatory review in more than 40 markets, with Lilly guiding to rollout in all major markets in 2027. In the U.S., it is one of the Bridge-relevant obesity products, but not the only one: Lilly’s filing explicitly points to Medicare uptake for Zepbound and Foundayo, while Mounjaro remains the diabetes-branded tirzepatide product rather than the obesity vehicle . If European reference pricing meets that rollout the way it met the injectables, both the 2027 revenue trajectory and the multiple compress at once. This is the single largest identifiable model risk, and I hold it as such rather than dismissing it.
The third is simply that the ex-US price reset is not finished. A 36 per cent decline in international realised price is a large number to lap, and the second half faces European summer seasonality and US type 2 diabetes seasonality that management has said are embedded in the guide . On top of that sit the two consolidated product-liability proceedings over gastrointestinal injury and ischaemic optic neuropathy claims tied to the incretins — genuinely unquantifiable, and a reason not to underwrite a maximal multiple.
Paying 24x for high-twenties growth
Management raised 2026 revenue guidance to $85bn–$87bn from $82bn–$85bn and lifted performance margin — its gross-margin-less-R&D-and-SG&A measure — to 49.0–50.5 per cent from 47.0–48.5 per cent, while holding non-GAAP EPS at $35.50–$36.50 because a $3.03 per-share acquired-IPR&D charge exactly offset a $2.78 underlying raise . The flat headline EPS range is an accounting artefact of dealmaking, not a downgrade; the operating guide went up on both lines that matter.
Against that, the shares trade at roughly 32x the consensus 2026 mean of $36.39 and about 25x the 2027 mean of $46.64, on a panel of twenty covering analysts . Consensus therefore embeds about 28 per cent EPS growth between those two years, putting the forward multiple at a PEG below 0.9 — for the fastest-compounding large-cap franchise in healthcare, one that just widened gross margin through a double-digit price cut. The contrast with the only true pure-play comparable is instructive: Novo Nordisk, capitalised at $207bn against Lilly's $1.08tn , carries a consensus 2027 earnings-per-share estimate below its 2025 reported level — the market is not paying a GLP-1 premium as a sector reflex, it is paying it to the operator taking share.
My own 2027 revenue estimate of $102bn sits modestly above the ~$99bn consensus mean on a faster Foundayo international ramp, with retatrutide — whose Phase 3 package across obesity, sleep apnea and knee osteoarthritis pain is complete and whose US filing is slated for the first quarter of 2027 — carried nowhere in the base. On 28x a 2027 non-GAAP EPS of $48.02 that produces a twelve-month value of about $1,345, roughly 17 per cent above the last close and a shade below the $1,350 twelve-month consensus target . A discounted-cash-flow cross-check on the same revenue track, discounted near 7.3 per cent with a 20x exit on free cash flow to the firm, lands far lower — near $810 — and the entire gap decomposes to the terminal multiple. That is the honest tension: if Lilly no longer commands a growth multiple in 2030, the earnings lens is too generous. On a twelve-month view, with the ex-US and oral ramps still early, I think the earnings lens is the better read and the cash-flow model's five-year window truncates the compounding before it inflects.
The market spent late August worrying about a hazard ratio that was never designed to be a differentiator and about a pricing regime Lilly negotiated in advance and got tariff protection for. It is not worrying enough about $23bn of debt-funded Phase 1 assets being credited at franchise economics. Net of that discount, at roughly 25x next year's consensus earnings for a business converting three-quarters of net income to cash and taking share on both sides of the Atlantic, Eli Lilly is mispriced to the upside — and the risk-reward has not turned, it has merely become less generous than it was at $712.
Disclaimer: Tenzing Analytics, Inc. is not a registered investment adviser, broker-dealer, or financial institution, and all content provided by Tenzing Memo is AI-generated for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy, sell, or hold any security or financial instrument. Content is general in nature, not tailored to any individual's financial situation or objectives, and may contain errors, omissions, or inaccuracies; it should not be relied upon as a primary basis for any investment decision. Any forward-looking statements are subject to risks and uncertainties and may not reflect actual future results. Users should conduct their own research and consult qualified financial, legal, or tax advisors before making investment decisions, and by accessing this content, you acknowledge and accept these limitations.